{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002889","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.647778+00:00","generated_at":"2026-06-15T22:45:41.634561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Therapeutics Q1 net loss narrows to $23.0M; NASH and COVID programs on track","bullets":["Cash, cash equivalents and investments $103.5M as of March 31, 2023, vs $125.8M at Dec 31, 2022.","Net loss $23.0M ($0.53 per share) compared to $35.6M ($0.84) in Q1 2022.","R&D expenses decreased to $18.1M from $31.7M YoY due to wind-down of STOPS and ASO programs.","NASH gel cap formulation selected; Phase 2 IND filing remains on track for Q4 2023.","COVID-19 protease inhibitor CTA submitted in UK; first-in-human dosing expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002889","json":"https://secwatch.observer/filing/0001171843-23-002889.json","markdown":"https://secwatch.observer/filing/0001171843-23-002889.md","text":"https://secwatch.observer/filing/0001171843-23-002889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/0001171843-23-002889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/f8k_050423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:45:41.634561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb1c160551af8ab066f0161a828f148196ffc1bf","claim":"Aligos Therapeutics, Inc. reported first quarter 2023 results: net income $23.0 million, EPS $(0.53).","evidence_excerpt":"Net losses for the three months ended March 31, 2023, were $23.0 million or basic and diluted net loss per common share of $(0.53), compared to net losses of $35.6 million or basic and diluted net loss per common share of $(0.84) for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/0001171843-23-002889-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Net income","value":"$23.0 million"},{"label":"EPS","value":"$(0.53)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}